stimulant - Page 1 | CARLAT PUBLISHING

Preschoolers and Stimulants: When Is Medication the Right Call for ADHD?

May 12, 2025

Joshua Feder, MD and Mara Goverman

Today, we’re tackling a big question: How young is too young to treat children with medication for ADHD?

Clinical Update

How to Select a Stimulant for Adult ADHD

March 1, 2025

Greg Malzberg, MD

Gregory Malzberg, MD. Attending Psychiatrist & Assistant Clinical Professor, Mount Sinai West, New York, NY. Creator, PsychoFarm.

Dr. Malzberg has no financial relationships with companies related to this material.

We have 30 stimulant formulations, but do all deserve prizes? We find a few with niche advantages, and three that rise to the top.

Stimulant Dosing

February 19, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

Dosing is not a collaborative venture when it comes to controlled substances, and here we look for the safe upper limits of stimulant dosing.

Expert Q&A

Adult ADHD Treatment Challenges

November 9, 2023

Lawrence H. Diller, MD

Lawrence D. Diller, MD.

Private practice in behavioral pediatrics/child and family psychotherapy, Walnut Creek, CA.

Dr. Diller has no financial relationships with companies related to this material.

Lawrence Diller takes a balanced view on stimulants in adult ADHD and shares practical tips on how to make the diagnosis and avoid medication misuse.

Clinical Update

The Antipsychotic-Stimulant Combo

September 1, 2023

Avneet Soin, MD., Chris Aiken, MD, and Deepti Anbarasan, MD.

Avneet Soin, MD. Psychiatry resident, NYU Grossman School of Medicine. Deepti Anbarasan, MD. Associate Professor, Psychiatry & Neurology, New York University, New York.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report; Assistant Professor, NYU Langone Department of Psychiatry; practicing psychiatrist, Winston-Salem, NC.

Deepti Anbarasan, MD. Associate Professor, Psychiatry & Neurology, New York University, New York

Dr. Soin, Dr. Anbarasan, and Dr. Aiken have no financial relationships with companies related to this material.

As antipsychotic indications have spread, more patients are taking them in combination with their opposite: a stimulant. We look at the risks, search for scenarios where it might make sense, and come up with an action plan for this paradoxical pairing.

Research Update

Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults

May 9, 2023

Talya Shahal, MD.

Talya Shahal, MD. Dr. Shahal has no financial relationships with companies related to this material.

Stimulants may not significantly increase cardiovascular adverse events in older adults after the first month.

How to Treat ADHD in Bipolar Disorder

November 5, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.

Atomoxetine: Myths and Truths

September 10, 2021

Jason Mallo, DO

Jason Mallo, DO. Attending psychiatrist, Maine Medical Center, Portland, ME. Dr. Mallo has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

From ADHD to off-label uses, we detail how to dose atomoxetine, how pharmacogenomic testing affects it, and how it compares with stimulants and the other antidepressant for ADHD, viloxazine (Qelbree).

Stimulants and Creativity

February 3, 2021

Sean Ransom, PhD.

Sean Ransom, PhD. Assistant Clinical Professor, Department of Psychiatry at the LSU Health Sciences Center - New Orleans, and Clinical Director, Cognitive Behavioral Therapy Center of New Orleans. Dr. Ransom has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Does ADHD bring creative strengths? Can stimulants dampen creative thought? New research suggests they can, but the effect varies by patient.

EXPERT Q&A

Reduced Life Expectancy in ADHD

February 11, 2020

Russell Barkley, PhD

Russell Barkley, PhD
Clinical Professor of Psychiatry at The Virginia Commonwealth University Medical Center, Department of Psychiatry and the Virginia Treatment Center for Children Dr. Barkley has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Russell Barkley, PhD, discusses the enormity of the health consequences and early mortality associated with ADHD. The range and likely mechanism of long-term effects of ADHD are discussed, and we examine the role of assertive treatment in childhood and adolescence.